Annals of Oncology shared a post on X:
“New article in press: Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.”
baybiosciences.com